Reuters logo
BRIEF-Redhill Biopharma reports enrollment of last patient in bekinda phase II study
April 24, 2017 / 11:24 AM / 8 months ago

BRIEF-Redhill Biopharma reports enrollment of last patient in bekinda phase II study

April 24 (Reuters) - Redhill Biopharma Ltd:

* Redhill Biopharma Ltd- Redhill Biopharma announces enrollment of last patient in bekinda phase II study for IBS-D

* Redhill Biopharma Ltd- top-line results are expected in Q3 of 2017

* Redhill Biopharma Ltd- top-line results from a phase III study with bekinda 24 mg for acute gastroenteritis and gastritis are expected in Q2 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below